Cargando…

Analysis of musculoskeletal side effects of oral Isotretinoin treatment: a cross-sectional study

BACKGROUND/ OBJECTIVES: Acne vulgaris is a chronic inflammatory disease affecting the pilosebaceous unit. Isotretinoin is an effective treatment option for severe acne. The aim of this study was to evaluate musculoskeletal side effects of systemic isotretinoin treatment. METHODS: Ninety-four patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Karaosmanoğlu, Nermin, Mülkoğlu, Cevriye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519514/
https://www.ncbi.nlm.nih.gov/pubmed/32977793
http://dx.doi.org/10.1186/s12891-020-03656-w
_version_ 1783587586527199232
author Karaosmanoğlu, Nermin
Mülkoğlu, Cevriye
author_facet Karaosmanoğlu, Nermin
Mülkoğlu, Cevriye
author_sort Karaosmanoğlu, Nermin
collection PubMed
description BACKGROUND/ OBJECTIVES: Acne vulgaris is a chronic inflammatory disease affecting the pilosebaceous unit. Isotretinoin is an effective treatment option for severe acne. The aim of this study was to evaluate musculoskeletal side effects of systemic isotretinoin treatment. METHODS: Ninety-four patients with acne vulgaris and 100 sex- and age-matched controls were enrolled in this study. Only the patients who had musculoskeletal symptoms were evaluated in this study. All participants were firstly assessed by a dermatologist. The patients were asked whether they had any musculoskeletal symptoms after isotretinoin treatment, if so, the feature and duration of the symptoms were recorded. The dosage of the drug, treatment duration, incidence of arthralgia, myalgia, low back pain, sacroiliitis and tendinopathy and laboratory test results were noted. The severity of pain was assessed by visual analog scale (VAS). The severity of acne vulgaris was evaluated by Global Acne Grading Scale (GAGS). Sacroiliac radiography, magnetic resonance imaging (MRI) and rheumatologic blood tests were requested from the patients meeting Assessment of Spondyloarthritis International Society (ASAS) criteria. RESULTS: Of the 94 patients, 71 were female and 23 were male. 47.9% of the patients had arthralgia, 53.2% had myalgia, 70.2% (66) had low back pain, 11.7% had sacroiliitis and 4.3% had tendinopathy. 37.8% of 66 patients with low back pain had inflammatory pain and 62.2% had mechanical pain. Bone marrow edema consistent with sacroiliitis was detected by sacroiliac MRI in 11 patients with inflammatory back pain. The median total cumulative dose of isotretinoin was significantly higher in patients with low back pain than in patients without low back pain (p = 0.014). There was no significant correlation between cumulative dose of drug, treatment duration and VAS with ESR and CRP (p > 0.05). Also no correlation was found between GAGS scores and musculoskeletal symptoms (p > 0.05). CONCLUSION: Low back pain is one of the very common complications of isotretinoin. It can be mostly mechanical or inflammatory. Isotretinoin-induced low back pain is dose-related, and inflammatory back pain without sacroiliitis is also frequent. The clinicians should be aware of the back pain may be a reflective of sacroiliitis during isotretinoin usage.
format Online
Article
Text
id pubmed-7519514
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75195142020-09-29 Analysis of musculoskeletal side effects of oral Isotretinoin treatment: a cross-sectional study Karaosmanoğlu, Nermin Mülkoğlu, Cevriye BMC Musculoskelet Disord Research Article BACKGROUND/ OBJECTIVES: Acne vulgaris is a chronic inflammatory disease affecting the pilosebaceous unit. Isotretinoin is an effective treatment option for severe acne. The aim of this study was to evaluate musculoskeletal side effects of systemic isotretinoin treatment. METHODS: Ninety-four patients with acne vulgaris and 100 sex- and age-matched controls were enrolled in this study. Only the patients who had musculoskeletal symptoms were evaluated in this study. All participants were firstly assessed by a dermatologist. The patients were asked whether they had any musculoskeletal symptoms after isotretinoin treatment, if so, the feature and duration of the symptoms were recorded. The dosage of the drug, treatment duration, incidence of arthralgia, myalgia, low back pain, sacroiliitis and tendinopathy and laboratory test results were noted. The severity of pain was assessed by visual analog scale (VAS). The severity of acne vulgaris was evaluated by Global Acne Grading Scale (GAGS). Sacroiliac radiography, magnetic resonance imaging (MRI) and rheumatologic blood tests were requested from the patients meeting Assessment of Spondyloarthritis International Society (ASAS) criteria. RESULTS: Of the 94 patients, 71 were female and 23 were male. 47.9% of the patients had arthralgia, 53.2% had myalgia, 70.2% (66) had low back pain, 11.7% had sacroiliitis and 4.3% had tendinopathy. 37.8% of 66 patients with low back pain had inflammatory pain and 62.2% had mechanical pain. Bone marrow edema consistent with sacroiliitis was detected by sacroiliac MRI in 11 patients with inflammatory back pain. The median total cumulative dose of isotretinoin was significantly higher in patients with low back pain than in patients without low back pain (p = 0.014). There was no significant correlation between cumulative dose of drug, treatment duration and VAS with ESR and CRP (p > 0.05). Also no correlation was found between GAGS scores and musculoskeletal symptoms (p > 0.05). CONCLUSION: Low back pain is one of the very common complications of isotretinoin. It can be mostly mechanical or inflammatory. Isotretinoin-induced low back pain is dose-related, and inflammatory back pain without sacroiliitis is also frequent. The clinicians should be aware of the back pain may be a reflective of sacroiliitis during isotretinoin usage. BioMed Central 2020-09-25 /pmc/articles/PMC7519514/ /pubmed/32977793 http://dx.doi.org/10.1186/s12891-020-03656-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Karaosmanoğlu, Nermin
Mülkoğlu, Cevriye
Analysis of musculoskeletal side effects of oral Isotretinoin treatment: a cross-sectional study
title Analysis of musculoskeletal side effects of oral Isotretinoin treatment: a cross-sectional study
title_full Analysis of musculoskeletal side effects of oral Isotretinoin treatment: a cross-sectional study
title_fullStr Analysis of musculoskeletal side effects of oral Isotretinoin treatment: a cross-sectional study
title_full_unstemmed Analysis of musculoskeletal side effects of oral Isotretinoin treatment: a cross-sectional study
title_short Analysis of musculoskeletal side effects of oral Isotretinoin treatment: a cross-sectional study
title_sort analysis of musculoskeletal side effects of oral isotretinoin treatment: a cross-sectional study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519514/
https://www.ncbi.nlm.nih.gov/pubmed/32977793
http://dx.doi.org/10.1186/s12891-020-03656-w
work_keys_str_mv AT karaosmanoglunermin analysisofmusculoskeletalsideeffectsoforalisotretinointreatmentacrosssectionalstudy
AT mulkoglucevriye analysisofmusculoskeletalsideeffectsoforalisotretinointreatmentacrosssectionalstudy